36 /100
MEDIUM RISK
Score updated Jul 13, 2026

CNTX — Context Therapeutics Inc. Dilution Risk Tracker

Track CNTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CNTX — Get alerts when the score changes →

As of July 13, 2026, Context Therapeutics Inc. (CNTX) has a DilutionWatch DilutionScore of 36/100, rated MEDIUM dilution risk. Context Therapeutics Inc. has a market capitalization of $261.86M, 91.88M shares outstanding, 61 institutional holders tracked. Key dilution vectors include approximately 25 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
10
📊 Float Risk
40
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
7%
🔄 Reverse Split 15%
• 52-week low $0.52 has breached $1
🔔 Track CNTX — Get forecast alerts →

💹 Market Data

Market Cap$261.86M
Shares Outstanding91.88M
Float42.82M
Cash$54.53M
Debt$282.4K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 13.6% shares (2026Q1 vs prior)
61 institutional holders · 82.93M shares
#1 MPM BIOIMPACT LLC 10.68M shares
#2 Avidity Partners Management LP 10.00M shares
#3 Nextech Invest, Ltd. 7.42M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest3.21M
Days to Cover1.0
% of Float7.5%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Jul 07, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2022
4 INSIDER TRANSACTION Jun 26, 2026
4 INSIDER TRANSACTION Jun 26, 2026
4 INSIDER TRANSACTION Jun 26, 2026
Full SEC filing analysis available with free account

📰 Recent News

📋 What This Means for CNTX Shareholders

Context Therapeutics Inc. (CNTX) has a DilutionScore of 36/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for CNTX shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for CNTX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for CNTX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track CNTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking CNTX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for CNTX
📊 CNTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 CNTX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.